[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA831387B - 1,2,4-triazine and pyrazine derivatives - Google Patents

1,2,4-triazine and pyrazine derivatives

Info

Publication number
ZA831387B
ZA831387B ZA831387A ZA831387A ZA831387B ZA 831387 B ZA831387 B ZA 831387B ZA 831387 A ZA831387 A ZA 831387A ZA 831387 A ZA831387 A ZA 831387A ZA 831387 B ZA831387 B ZA 831387B
Authority
ZA
South Africa
Prior art keywords
triazine
pyrazine derivatives
gaba
triazines
diaryl
Prior art date
Application number
ZA831387A
Other languages
English (en)
Inventor
Taiwai Wong David
Bryant Lacefield William
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA831387B publication Critical patent/ZA831387B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16Halogen atoms; Nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA831387A 1982-03-05 1983-03-01 1,2,4-triazine and pyrazine derivatives ZA831387B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/354,982 US4513135A (en) 1982-03-05 1982-03-05 Diaryl-pyrazine derivatives affecting GABA binding

Publications (1)

Publication Number Publication Date
ZA831387B true ZA831387B (en) 1984-10-31

Family

ID=23395746

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA831387A ZA831387B (en) 1982-03-05 1983-03-01 1,2,4-triazine and pyrazine derivatives

Country Status (22)

Country Link
US (2) US4513135A (xx)
EP (1) EP0088593B1 (xx)
JP (1) JPS58162582A (xx)
KR (1) KR860000847B1 (xx)
AT (1) ATE27457T1 (xx)
AU (1) AU547581B2 (xx)
CA (1) CA1195327A (xx)
DD (1) DD207716A5 (xx)
DE (1) DE3371786D1 (xx)
DK (1) DK97283A (xx)
ES (2) ES8404346A1 (xx)
FI (1) FI830708L (xx)
GB (1) GB2116179B (xx)
GR (1) GR78459B (xx)
HU (1) HU191368B (xx)
IL (1) IL68002A (xx)
NZ (1) NZ203428A (xx)
PH (1) PH22535A (xx)
PL (1) PL240871A1 (xx)
PT (1) PT76312B (xx)
RO (1) RO86320B (xx)
ZA (1) ZA831387B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) * 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
WO1992002513A1 (en) * 1990-08-06 1992-02-20 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
TWI316055B (xx) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
WO2006084119A2 (en) * 2005-02-01 2006-08-10 Lake Erie Products Anti-cross threading fastener
US20070078135A1 (en) * 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
BR112012019540B1 (pt) 2010-02-05 2021-09-28 Heptares Therapeutics Limited Composto, uso de um composto, formulação farmacêutica, e, processo para a preparação de um composto
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
MX395351B (es) 2016-07-12 2025-03-25 Revolution Medicines Inc 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
JP6918828B2 (ja) * 2016-11-30 2021-08-11 田辺三菱製薬株式会社 トリアジン化合物の製造方法
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ,インコーポレイテッド がんを治療するためのshp2阻害剤組成物および方法
WO2019075265A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. PYRIDINE, PYRAZINE AND TRIAZINE COMPOUNDS AS ALLOSTERIC INHIBITORS OF SHP2
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
KR20210018244A (ko) 2018-05-01 2021-02-17 레볼루션 메디슨즈, 인크. mTOR 억제제로서의 C40-, C28- 및 C-32-연결된 라파마이신 유사체
SG11202010560QA (en) 2018-05-01 2020-11-27 Revolution Medicines Inc C26-linked rapamycin analogs as mtor inhibitors
EP4531859A1 (en) 2022-05-25 2025-04-09 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172889A (en) * 1965-03-09 Process for the separation of z-methyl-
US3294638A (en) * 1961-06-05 1966-12-27 Warner Lambert Pharmaceutical Method and compositions employing 2-alkyl-3-piperidinopyrazines
CH480795A (de) * 1967-03-01 1969-11-15 Sandoz Ag Mittel zur Beeinflussung des Pflanzenwachstums
US4013654A (en) * 1974-01-31 1977-03-22 Eli Lilly And Company 5,6-diaryl-1,2,4-triazines
US3979516A (en) * 1974-01-31 1976-09-07 Eli Lilly And Company Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines
US3989831A (en) * 1974-01-31 1976-11-02 Eli Lilly And Company Topically-active anti-inflammatory 3-chloro-5,6-diaryl-1,2,4-triazines
US3948894A (en) * 1974-01-31 1976-04-06 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4081542A (en) * 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
GB1493998A (en) * 1975-06-03 1977-12-07 Beecham Group Ltd Propanolamine derivatives
US4008232A (en) * 1975-06-23 1977-02-15 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4082844A (en) * 1976-02-09 1978-04-04 Merck & Co., Inc. 6-chloro-2-(1-piperazinyl)pyrazine
US4190725A (en) * 1976-03-10 1980-02-26 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines
US4018923A (en) * 1976-03-10 1977-04-19 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
US4021553A (en) * 1976-03-10 1977-05-03 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
DE2810052A1 (de) * 1977-03-09 1978-09-14 Fabre Sa Pierre Aminoaryl-1,2,4-triazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4157392A (en) * 1977-05-17 1979-06-05 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
GB1604085A (en) * 1977-05-17 1981-12-02 Diamond Shamrock Corp Pharmaceutical preparations containing 1,2,4-triazine derivatives
US4251527A (en) * 1977-05-17 1981-02-17 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines

Also Published As

Publication number Publication date
IL68002A (en) 1986-09-30
JPS58162582A (ja) 1983-09-27
AU1202983A (en) 1983-09-08
ES520340A0 (es) 1984-04-16
KR860000847B1 (ko) 1986-07-09
DK97283A (da) 1983-09-06
ES526297A0 (es) 1985-04-16
RO86320A (ro) 1985-03-15
IL68002A0 (en) 1983-06-15
PT76312B (en) 1986-02-04
US4513135A (en) 1985-04-23
DK97283D0 (da) 1983-02-28
DD207716A5 (de) 1984-03-14
NZ203428A (en) 1986-09-10
KR840004101A (ko) 1984-10-06
HU191368B (en) 1987-02-27
US4585861A (en) 1986-04-29
FI830708A0 (fi) 1983-03-02
FI830708A7 (fi) 1983-09-06
GB2116179A (en) 1983-09-21
AU547581B2 (en) 1985-10-24
PL240871A1 (en) 1984-06-18
ES8504173A1 (es) 1985-04-16
ATE27457T1 (de) 1987-06-15
EP0088593B1 (en) 1987-05-27
FI830708L (fi) 1983-09-06
GB8305846D0 (en) 1983-04-07
ES8404346A1 (es) 1984-04-16
EP0088593A3 (en) 1984-05-23
CA1195327A (en) 1985-10-15
GB2116179B (en) 1985-09-11
PT76312A (en) 1983-04-01
DE3371786D1 (en) 1987-07-02
EP0088593A2 (en) 1983-09-14
PH22535A (en) 1988-10-17
GR78459B (xx) 1984-09-27
RO86320B (ro) 1985-03-31

Similar Documents

Publication Publication Date Title
GB2116179B (en) 1,2,4-triazine and pyrazine derivatives
ES8801546A1 (es) Un procedimiento para la preparacion de compuesto de 2,2-difluoronucleosidos.
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
DE3369590D1 (en) Bismaleimide triazine composition
IE811431L (en) Pyrazinyl oxadiazoles
PH19424A (en) 2-substituted 4 amino 6,7 dimethoxyquinolines
ES8203375A1 (es) Procedimiento de preparar triazoloquinoxalin-4-onas substi- tuidas antihipertensoras
BG45552A3 (bg) Метод за получаване на 2-фенил-хексахидро-1,2,4- триазин-3,5-диони
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
EP0295350A3 (en) Use of n-û2-(diethylamino)ethyl¨-2-methoxy-4-û(1-h 4,5-dihydro-2-imidazolyl)amino¨-5-chlorobenzamide as an anxiolytic and antipsychotic agent
GB2138418B (en) Novel s-triazole(1,5-a)pyrimidine derivatives
ES8601849A1 (es) Un procedimiento para la preparacion de ariloxicicloalcanolaminoalquilen aril cetonas
SU1089968A1 (ru) Магнитореологическая суспензия
IT8323139A0 (it) Caviglia per l'assemblaggio di parti di mobili.
PL252065A1 (en) Method of obtaining 2,3,4,5-tetrahydro-1h-/1,4/diazepin /1,7-a/indoles
SU1102116A2 (ru) Реакционная камера
DE3461189D1 (en) New 3-alkylthio-2-o-carbamoyl-propane-1.2-diol-1-o-phosphocholines, and processes for their preparation
SU1083739A1 (ru) Стокс-калибратор
SU1120886A1 (ru) P-i-n-ДИОД
RO87212B1 (ro) Derivati de p-fluorbenzamida
GB2130575B (en) Amide derivatives of 13, 14-didehydro-cycloalkyl-prostaglandins
SU1111454A1 (ru) Способ получения (4,6-дизамещенный пиримидинил-2)тиофанийбромидов
SU1220308A1 (ru) Производные дигидропирроло [1,2,3-e,d]пиримидо [4,5-b]пиразина или дигидропирроло [1,2,3-e,d]пиримидо[4,5-b]диазепина и способ их получения
SU1195570A1 (ru) Багажник-палатка крыши автомобиля